sellModerate cluster of 610b5-1 plan
BENKOWITZ MICHAEL sold $3.6M of UTHR
PRESIDENT AND COO at UNITED THERAPEUTICS Corp. 10,000 shares at an average of $359.21, traded Nov 18, 2024, filed Nov 19, 2024.
Warning score
45Value
$3.6M
10,000 shares
Holdings after
0
-133% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001415889-24-027219, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 18, 2024 | MOption exercise Common Stockindirect: By Trust10b5-1 | +7,500 | $102.11 | $766k | 7,500 | Nov 19, 2024 |
| Nov 18, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -901 | $357.03 | $322k | 6,599 | Nov 19, 2024 |
| Nov 18, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -1,099 | $358.00 | $393k | 5,500 | Nov 19, 2024 |
| Nov 18, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -2,921 | $359.01 | $1.0M | 2,579 | Nov 19, 2024 |
| Nov 18, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -1,443 | $360.31 | $520k | 1,136 | Nov 19, 2024 |
| Nov 18, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -899 | $361.20 | $325k | 237 | Nov 19, 2024 |
| Nov 18, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -237 | $362.02 | $86k | 0 | Nov 19, 2024 |
| Nov 18, 2024 | MOption exercise Common Stockindirect: By Trust10b5-1 | +2,500 | $111.00 | $278k | 2,500 | Nov 19, 2024 |
| Nov 18, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -200 | $356.42 | $71k | 2,300 | Nov 19, 2024 |
| Nov 18, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -447 | $357.79 | $160k | 1,853 | Nov 19, 2024 |
| Nov 18, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -846 | $358.89 | $304k | 1,007 | Nov 19, 2024 |
| Nov 18, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -500 | $359.64 | $180k | 507 | Nov 19, 2024 |
| Nov 18, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -307 | $360.95 | $111k | 200 | Nov 19, 2024 |
| Nov 18, 2024 | SOpen-market sale Common Stockindirect: By Trust10b5-1 | -200 | $361.86 | $72k | 0 | Nov 19, 2024 |
| Nov 18, 2024 | MOption exercise Stock Optionsderivativeindirect: By Trust10b5-1 | -7,500 | $0.00 | $0 | 19,500 | Nov 19, 2024 |
| Nov 18, 2024 | MOption exercise Stock Optionsderivativeindirect: By Trust10b5-1 | -2,500 | $0.00 | $0 | 39,500 | Nov 19, 2024 |
Related signals
Other insiders at UNITED THERAPEUTICS Corp and this insider’s other filings.
| Score | Side | Company | Insider | Value | Shares | Filed |
|---|---|---|---|---|---|---|
| 45Moderate | sell 310b5-1 | UTHR UNITED THERAPEUTICS Corp | BENKOWITZ MICHAEL PRESIDENT AND COO | $3.6M | 10,000 | |
| 39Weak | sell 3 | UTHR UNITED THERAPEUTICS Corp | Mesa Nilda director | $91k | 255 | |
| 45Moderate | sell 310b5-1 | UTHR UNITED THERAPEUTICS Corp | BENKOWITZ MICHAEL PRESIDENT AND COO | $3.6M | 10,000 | |
| 60Notable | sell 4 | UTHR UNITED THERAPEUTICS Corp | SULLIVAN LOUIS W director | $9.8M | 26,209 | |
| 45Moderate | sell 410b5-1 | UTHR UNITED THERAPEUTICS Corp | BENKOWITZ MICHAEL PRESIDENT AND COO | $3.7M | 10,000 | |
| 45Moderate | sell 310b5-1 | UTHR UNITED THERAPEUTICS Corp | BENKOWITZ MICHAEL PRESIDENT AND COO | $3.7M | 10,000 | |
| 25Weak | sell 310b5-1 | UTHR UNITED THERAPEUTICS Corp | MAHON PAUL A EVP & GENERAL COUNSEL | $2.9M | 7,700 | |
| 38Weak | sell 210b5-1 | UTHR UNITED THERAPEUTICS Corp | BENKOWITZ MICHAEL PRESIDENT AND COO | $3.7M | 10,000 | |
| 45Moderate | sell 310b5-1 | UTHR UNITED THERAPEUTICS Corp | BENKOWITZ MICHAEL PRESIDENT AND COO | $3.7M | 10,000 | |
| 25Weak | sell 410b5-1 | UTHR UNITED THERAPEUTICS Corp | MAHON PAUL A EVP & GENERAL COUNSEL | $2.8M | 7,700 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.